D.E. Shaw & Co
ANRO icon

D.E. Shaw & Co’s Alto Neuroscience ANRO Stock Holding History

D.E. Shaw & Co’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.02M Sell
45,343
-79,452
-64% -$1.47M ﹤0.01% 3426
2025
Q4 		$2.22M Buy
+124,795
New +$1.57M ﹤0.01% 2972

Other funds holding ANRO

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co's ANRO Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Alto Neuroscience (ANRO) stake by 64% in Q1 2026, selling an estimated $1.47M and leaving 45,343 shares worth $1.02M. The position accounts for ﹤0.01% of the portfolio, ranked #3426.

D.E. Shaw & Co first reported a position in ANRO in Q4 2025 and has held it in 2 quarters since. The position peaked at $2.22M in Q4 2025. 110 funds tracked by Wall St. Rank hold ANRO as of Q1 2026.

  • D.E. Shaw & Co held 45,343 shares of Alto Neuroscience worth $1.02M as of Q1 2026.
  • D.E. Shaw & Co sold 79,452 Alto Neuroscience shares in Q1 2026, an estimated $1.47M.
  • Alto Neuroscience made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #3426 holding.
  • D.E. Shaw & Co first reported a position in Alto Neuroscience in Q4 2025 and has held it in 2 quarters since.
  • D.E. Shaw & Co's Alto Neuroscience position peaked at $2.22M in Q4 2025.
  • 110 funds tracked by Wall St. Rank held Alto Neuroscience as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.